CYP Assay Service
Product Classification : hiPSC-HepatocytesResearch Theme : Drug metabolism
Custom evaluation of compound effects on CYP3A4 expression and activity
- Detection method: Luminescence using P450-Glo™ CYP3A4 assay (Luciferin-PFBE) cell-based/biochemical assay (Promega)
- Reported content: The absolute and relative values of luminescence. The relative value is the absolute value combined with the provided compound treatment (induced activity) divided by the absolute value of untreated cells (basal activity). Assay results are provided as digital data or printed material on request.
- Material: Our in-house human iPS cell-derived hepatocytes ReproHepato™, cultured and assayed in 96-well plate format.
- Number of measurable data points: 72 wells (The remaining wells are used as controls)
Assay example plan
Example 1: 3 compounds × 8 doses, n = 3
Example 2: 4 compounds × 6 doses, n = 3
Example 3: 6 compounds × 4 doses, n = 3
- Lead time: Approximately 1 month from start date
- Please note: The solvent used for test compounds is methanol. If a different solvent is preferred, please consult us. Assay details can be custom tailored to your needs.
High-purity CYP-positive hepatocytes derived from human iPS cells
ReproHepato™ cells have typical human hepatocyte-like morphology and characteristics. The expression of key hepatic components such as CYP3A4, HNF4a, E-cadherin, and albumin in high percentages of ReproHepato™ cells is indicative of the high purity of these cells.
Robust CYP activity and induction
CYP3A4 activity is modulated by typical inducers and inhibitors in a dose-dependent manner, as in the case of primary hepatocytes. Activity and inducibility of other CYPs (1A2/2C9/2C19) is also observed at levels comparable to those of primary hepatocytes.
Small lot-to-lot variation leading to more consistent results
Compared to primary hepatocytes, ReproHepato™ hepatocytes show less lot-to-lot variation in CYP activity and inducibility.
Basal and rifampicin-induced CYP3A4 activity
Fold change of CYP3A4 activity
Long life in culture
ReproHepato can be cultured for an extended period while retaining hepatic functions. Contact ReproCELL for more information.
- Society for Biomolecular Sciences(SBS), 14th AnnualConference & Exhibition 2008 (St. Louis), poster session, April 2008.
- IBC Asia's 4th Annual Stem Cells Asia Congress (Singapore), oral session, June 2008.
- ELRIG and SBS Present: Drug Discovery (UK) poster session, September 2008.
- Advances in Stem Cell Discoveries (San Francisco) oral session, September 2008.
- Stem Cells: Drug Discovery and Therapeutics (London) oral session, February 2008.
- Society for Biomolecular Science 15th Annual Conference (France), poster session, Best Poster 2009 Award-winning, April 2009.
- Stem Cells and Regenerative Medicine Europe (UK), September 2009, Best Poster 2009 Award-winning.
- MipTec Conference 2009, October 13-15, Basel Invited Lecture.
- The 74th Annual Scientific Meeting of the Japanese Circulation Society（Kyoto）, March 2010.
- The 130th The Pharmaceutical Society of Japan（Okayama）, March 2010.
- The Society of Toxicology (SOT) 51st Annual Meeting (CA, USA), poster session, March 2012.
- Safety Pharmacology Society (SPS), 13th annual meeting 2013 (Rotterdam, Netherlands), poster session, September 2013.
- Automated Patch-Clamp systems and Ion Channel Expressing Cells 2013 (Tokyo), Verbal presentation 2013 Nov.
- The 7th Takeda Science Foundation Symposium (Osaka), Poster presentation 2014 Jan.
- Inamura, Mitsuru and Yokoyama, Chikafumi. "Human iPS cell-derived hepatocytes for drug screening." Regenerative Medicine (2013)
- Scott, Clay W., Matthew F. Peters, and Yvonne P. Dragan. "Human induced pluripotent stem cells and their use in drug discovery for toxicity testing." Toxicology letters 219.1 (2013): 49-58.
- Inamura, Mitsuru and Yokoyama, Chikafumi. “Human iPS cell-derived hepatocytes for drug screening.” Regenerative Medicine (2013)
- Scott, Clay W., Matthew F. Peters, and Yvonne P. Dragan. “Human induced pluripotent stem cells and their use in drug discovery for toxicity testing.” Toxicology letters 219.1 (2013): 49-58.
Service order information
|RCESDH401||CYP Assay Service||Ask|